Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study
Pacing and Clinical Electrophysiology · 2025
DOI: 10.1111/pace.15142 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pacing and Clinical Electrophysiology, 2025. Verfasst von Fankun Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Cardiomyopathies, Death, Sudden, Cardiac, Primary Prevention. Die Arbeit nennt 23 Literaturangaben. Gefördert von: the National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
The evidence in the primary prevention of sudden cardiac death (SCD) by using implantable cardioverter defibrillators (ICD) in patients with ischemic cardiomyopathy (ICM) is well‐established but remains controversial for those with nonischemic cardiomyopathy (NICM). This study evaluates whether prognostic differences exist between ICM and NICM patients after ICD implantation.
Methods
Patients initially undergoing ICD implantation as primary SCD prevention were retrospectively enrolled from January 2017 to May 2023. Malignant ventricular arrhythmic and/or SCD were set as the primary endpoint, whereas all‐cause mortality was the secondary endpoint. Patients were grouped by heart failure etiology (ICM vs. NICM) and then by primary endpoint events occurrence. Outcomes analyses were performed between the NICM and ICM patients.
Results
The final cohort had 342 patients, 213 (62.3%) with NICM and 129 (37.7%) with ICM. At a median follow‐up of 23.0 (10.7, 33.2) months, 51 patients (14.9%) encountered primary endpoint events. No statistically significant disparities in primary endpoint events (log rank p = 0.413), all‐cause death (log rank p = 0.208), cardiovascular mortality (log rank p = 0.218), or appropriate ICD therapy (log rank p = 0.250) between the two groups were indicated by Kaplan–Meier survival analysis. Moreover, the COX‐adjusted models further demonstrated the absence of any significant differences between the two groups.
Conclusion
In real‐world settings, primary prevention of SCD with ICD implantation yields similar outcomes for ICM and NICM patients, including probabilities of SCD and/or malignant ventricular arrhythmias, all‐cause mortality, appropriate ICD therapy, and cardiovascular mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
ORCID-Profile: Fankun Ma, Haibo Yu, Yanchun Liang
Förderung
- the National Key Research and Development Program of China
Zitieren
APA
Ma, F., Gao, Y., Yu, H., Xu, G., Wu, M., Hao, X., Cui, Y., Peng, X., & Liang, Y. (2025). Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15142
Vancouver
Ma F, Gao Y, Yu H, Xu G, Wu M, Hao X, et al. Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.15142
BibTeX
@article{Ma2025,
author = {Ma, Fankun and Gao, Yang and Yu, Haibo and Xu, Guoqing and Wu, Min and Hao, Xinrui and Cui, Yangfan and Peng, Xiao and Liang, Yanchun},
title = {Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study},
journal = {Pacing and Clinical Electrophysiology},
year = {2025},
doi = {10.1111/pace.15142}
}
EUVIMED